Introduction to the food and drug administration (FDA) regulatory process

被引:12
作者
Hackett, JL
Gutman, SI
机构
[1] Office of in Vitro Diagnostic Device Evaluation and Safety, Food and Drug Administration
关键词
genomics; proteomics; FDA; in vitro diagnostic; biomarkers; pre-IDE;
D O I
10.1021/pr050059a
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
FDA oversight of medical devices, including in vitro diagnostic devices (IVDs or laboratory tests), in the United States was a direct result of the passage of the Medical Device Amendments of 1976. This law introduced a series of general controls for medical devices including registration and listing, requirements for production using good manufacturing practices, and requirements for post-market reporting of device failures. This produced for the first time a menu of laboratory tests on the market, a system to ensure these were produced consistently over time, and a mechanism for FDA to identify problems with device use and to work with companies to ensure corrective action. This law also introduced the requirement for premarket review of new versions of old devices and of fundamentally new medical devices.
引用
收藏
页码:1110 / 1113
页数:4
相关论文
共 5 条
[1]   Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative [J].
Bossuyt, PM ;
Reitsma, JB ;
Bruns, DE ;
Gatsonis, CA ;
Glasziou, PP ;
Irwig, LM ;
Lijmer, JG ;
Moher, D ;
Rennie, D ;
de Vet, HCW .
CLINICAL CHEMISTRY, 2003, 49 (01) :1-6
[2]   The STARD initiative and the reporting of studies of diagnostic accuracy [J].
Bruns, DE .
CLINICAL CHEMISTRY, 2003, 49 (01) :19-20
[3]  
*FDA US DEP HHS, 2004, CRIT PATH NEW MED PR
[4]   Decision making in pharmacogenomic diagnosis: is there anything new under the sun? [J].
Gutman, S ;
Feigal, D .
DRUG DISCOVERY TODAY, 2003, 8 (17) :765-766
[5]  
MCGUIRE WL, 1975, CANCER, V36, P638